Get the Stockscreener App
2.775
4.31%
-0.125
Compass Therapeutics Inc stock is traded at $2.775, with a volume of 396.60K.
It is down -4.31% in the last 24 hours and down -9.90% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
See More
Previous Close:
$2.90
Open:
$2.9
24h Volume:
396.60K
Relative Volume:
0.30
Market Cap:
$385.36M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-7.9286
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
-10.77%
1M Performance:
-9.90%
6M Performance:
+83.77%
1Y Performance:
+46.05%
1-Day Range:
$2.67
$3.0169
1-Week Range:
$2.67
$3.19
52-Week Range:
$0.765
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.775 | 385.36M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.07 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.05 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.23 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Research Analysts Issue Forecasts for CMPX Q1 Earnings - Defense World
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D. Boral Capital Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics shares rise on pipeline progress By Investing.com - Investing.com Canada
Compass Therapeutics shares rise on pipeline progress - Investing.com
Compass Therapeutics Reports 2024 Financial Results - TipRanks
Compass Therapeutics reports Q4 EPS (11c), consensus (9c) - TipRanks
Compass Therapeutics, Inc. SEC 10-K Report - TradingView
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Guggenheim - MarketBeat
Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - Nasdaq
Compass stock gains amid Guggenheim buy rating - MSN
Compass stock gains amid Guggenheim buy rating (CMPX:NASDAQ) - Seeking Alpha
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Compass Therapeutics: Good Execution, Major Catalysts Ahead (NASDAQ:CMPX) - Seeking Alpha
Guggenheim Initiates Compass Therapeutics at Buy With $12 Price Target -February 24, 2025 at 07:24 am EST - Marketscreener.com
Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Piper Sandler - MarketBeat
Massachusetts-Based Biotech Soars On Analyst Coverage And Bullish Price Targer - The Globe and Mail
Piper Sandler Initiates Coverage of Compass Therapeutics (CMPX) with Overweight Recommendation - Nasdaq
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Piper Sandler Initiates Compass Therapeutics at Overweight -February 19, 2025 at 09:07 am EST - Marketscreener.com
Piper Sandler initiates coverage on Compass Therapeutics with 'overweight' rating - TradingView
Piper Sandler sets $12 target on Compass Therapeutics stock By Investing.com - Investing.com UK
Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline - TipRanks
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update - MarketBeat
Chronic Pulmonary Hypertension Market Expected to rise, 2034 | COMPASS Pathways, Homeostasis Therapeutics, LLC, expected to drive market - The Globe and Mail
Compass Therapeutics (NASDAQ:CMPX) Trading Down 7.6%Here's Why - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Sets New 52-Week High on Analyst Upgrade - MarketBeat
Leerink Partnrs Has Strong Outlook for CMPX FY2024 Earnings - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Purchased by Bleakley Financial Group LLC - Defense World
Compass Therapeutics (NASDAQ:CMPX) & Cardiff Oncology (NASDAQ:CRDF) Critical Review - Defense World
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow - The Globe and Mail
Organon (OGN) Q4 Earnings Report Preview: What To Look For - The Globe and Mail
Molson Coors (TAP) Q4 Earnings: What To Expect - The Globe and Mail
Procter & Gamble Co: Rising -7.15% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Jefferies Financial Group Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.93%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):